Literature DB >> 29065824

Statins and vulnerable plaque.

Maria Drakopoulou1, Konstantinos Toutouzas1, Archontoula Michelongona1, Dimitrios Tousoulis1.   

Abstract

BACKGROUND: Atherosclerosis is a systemic, progressive lipid-driven inflammatory disease of the arterial vascular wall leading progressively to plaque development. The vulnerable plaque, the one considered to be the leading cause of cardiovascular events seems to exhibit a large and soft lipid-rich necrotic core covered by a thin and inflamed fibrous cap. Statin treatment is considered as one of the most effective methods for vulnerable plaque stabilization, currently being the principal drug in primary and secondary prevention of cardiovascular disease.
OBJECTIVE: We sought to evaluate the beneficial effect of statins on biological processes involved in the evolution of vulnerable plaques Method: We performed a systematic review of the literature searching MEDLINE via Pubmed for all experimental and human studies implementing statins in vulnerable plaque.
RESULTS: Statins seem to have a beneficial role in plaque stabilization and patient outcome. It seems that this effect is mediated by improving endothelial function, decreasing oxidative stress and inflammation, reducing inflammatory activation and inhibiting thrombogenic response. Although these data are quite promising, it remains to be determined the extent of a potent benefit of the pleiotropic effects of statin therapy in clinical setting.
CONCLUSION: Prospective randomized trials should be conducted in order to further elucidate differences among type and dose of statin therapy, duration of treatment and association with LDL levels and clinical outcome. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Atherosclerosis; imaging modalities; statin; vulnerable plaque

Year:  2017        PMID: 29065824     DOI: 10.2174/1381612823666171019161609

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  1 in total

1.  Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization.

Authors:  Fabiana Baganha; Rob C M de Jong; Erna A Peters; Wietske Voorham; J Wouter Jukema; Mirela Delibegovic; Margreet R de Vries; Paul H A Quax
Journal:  Angiogenesis       Date:  2021-02-07       Impact factor: 9.596

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.